ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine MARLBOROUGH, Mass. and AMSTERDAM, Aug. 27, 2023 /PRNewswire/ — Boston Scientific Corporation…
Comments Off on ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints